Meanwhile, PR expression in BRCA1-associated tumors is lower than that in sporadic tumors [5], thus making breast tumors in patients with BRCA1 mutations more likely to be classified as triple-negative breast cancer, characterized by the loss of ER and PR expression and HER2 overexpression. This evidence concerns the gene BRCA1 and triple-negative breast carcinoma.